Introduction {#s1}
============

High-grade hemorrhage is a significant cause of morbidity and mortality in patients with cancer [@pone.0074872-Pawarode1], [@pone.0074872-Carron1], [@pone.0074872-Nichols1], [@pone.0074872-Chait1]. Although the presence of malignancy itself and its associated physiologic changes are likely major contributors to an increased risk of hemorrhage, several cancer treatments, including targeted agents, cytotoxic agents, and supportive care medications [@pone.0074872-Elting1], [@pone.0074872-Levine1], [@pone.0074872-Hapani1], [@pone.0074872-Je1], [@pone.0074872-Hang1], have also been associated with increased risk of hemorrhage. Since first approved in 1996 for the treatment of unresectable pancreatic carcinoma, gemcitabine, a widely used pyrimidine antimetabolite that interferes with DNA synthesis, has been shown to be active in other solid tumors [@pone.0074872-Burris1], [@pone.0074872-Frasci1], [@pone.0074872-Culine1], [@pone.0074872-Oettle1], [@pone.0074872-DeSantis1], [@pone.0074872-Addeo1], [@pone.0074872-Valle1], [@pone.0074872-PazAres1]. Although common adverse events associated with gemcitabine are myelosuppression and mild liver function abnormalities [@pone.0074872-Eli1], high-grade hemorrhage (grade≥3) has been sporadically reported in several randomized controlled trials (RCTs) [@pone.0074872-Crino1], [@pone.0074872-Sandler1], [@pone.0074872-vonderMaase1], [@pone.0074872-Gridelli1], [@pone.0074872-Georgoulias1], [@pone.0074872-Zielinski1], [@pone.0074872-Gridelli2]. However, the risk of high-grade bleeding in cancer patients receiving gemcitabine that has been reported in clinical trials has not been completely consistent, and none of these trials is large enough to define the overall risk. In addition, an individual trial may be limited to the study of one tumor type. Therefore, we propose that pooling analyses of the current studies may provide a better understanding of the overall risk of high-grade bleeding among cancer patients who receive gemcitabine. As a result, we performed a systematic review and meta-analysis of RCTs to evaluate the incidence and relative risk (RR) of high-grade hemorrhage in cancer patients receiving gemcitabine-based versus non-gemcitabine-based chemotherapy.

Methods {#s2}
=======

Data Source {#s2a}
-----------

The selection and systematic review of trials was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement (see [Checklist S1](#pone.0074872.s001){ref-type="supplementary-material"}) [@pone.0074872-MoherD1]. Trials were selected from those published in PubMed between January 1, 1990, and December 31, 2012, with "gemcitabine," "cancer," "carcinoma", and "randomized clinical trial" as keywords. Only trials published in peer-reviewed publications in full manuscript form in English were eligible. Only the most recent publication was included when duplicates were identified.

Study Selection {#s2b}
---------------

Our primary objective was to evaluate the association between treatment with gemcitabine-based therapy and high-grade hemorrhage in patients with cancer. Clinical trials meeting the following criteria were included in the meta-analysis: 1) prospective randomized controlled phase II or III trial of cancer patients, 2) random assignment of participants to treatment with gemcitabine or non-gemcitabine-containing therapy, and 3) available data on high-grade hemorrhage. The quality of reports of clinical trials was assessed and calculated using the 5-item Jadad scale including randomization, double-blinding, and withdrawals as previously described [@pone.0074872-Moher1].

Data Extraction and Clinical End Point {#s2c}
--------------------------------------

Data extraction was conducted independently by two investigators (Y.H. and W.J.), and any discrepancy between the reviewers was resolved by consensus. For each study, the following information was extracted: author, publication year, trial phase, treatment arms, number of patients enrolled, number evaluable for toxicity, underlying malignancy, median age, median treatment duration, median progression-free survival, adverse outcomes of interest (high-grade hemorrhagic events), gemcitabine dosage (mg/m^2^). The following adverse outcomes were considered as hemorrhagic events and included in the main analysis: ecchymosis or petechiae; epistaxis; eye hemorrhage; gastrointestinal hemorrhage; gum hemorrhage; injection-site hemorrhage; hematemesis; hematuria; hemoptysis; non-specific hemorrhage; hemothorax; melaena; menorrhagia; metrorrhagia; purpura; rectal hemorrhage; retroperitoneal hemorrhage; CNS hemorrhage; and vaginal hemorrhage (includes menorrhagia and metrorrhagia). We also included (when available) the incidences of high-grade (grade 3 or above) hemorrhagic events. We assessed and recorded adverse events according to the National Cancer Institute's common toxicity criteria (version 2 or 3), which have been adopted widely in cancer clinical trials [@pone.0074872-NCI1].

Statistical Analysis {#s2d}
--------------------

All analyses were performed using Stata version 12.0 software (Stata Corporation, College Station, Texas, USA) and Open Meta-Analyst software version 4.16.12 (Tufts University, URL <http://tuftscaes.org/open_meta/>). For the calculation of incidence, the number of patients with high-grade hemorrhagic events and the number of patients receiving gemcitabine were extracted from the selected clinical trials; the proportion of patients with high-grade hemorrhagic events and 95% confidence interval (CI) were derived for each study. For the calculation of relative risk (RR), patients assigned to gemcitabine-based therapy were compared only with those assigned to control treatment in the same trial. Between-study heterogeneity was estimated using the χ^2^-based Q statistic [@pone.0074872-Zintzaras1]. Heterogeneity was considered statistically significant when *P* ~heterogeneity~ \<0.1. If heterogeneity existed, data was analyzed using a random effects model (DerSimonian Larid method). In the absence of heterogeneity, a fixed effects model was used (Mantel-Haenszel method). Continuity corrections with 0.5 were adopted for trials with zero events in either or both arms. A two-sided *p*-value less than 0.05 was considered significant. Prespecified subgroup analyses were performed according to tumor type, phase of trials, publication year or treatment regimens. To assess the stability of results, sensitivity analysis was performed by sequential omission of individual studies. The presence of publication bias was evaluated by using the Begg and Egger tests [@pone.0074872-Yusuf1], [@pone.0074872-Begg1].

Results {#s3}
=======

Systematic Literature Search {#s3a}
----------------------------

The literature search yielded 1457 publications describing the use of gemcitabine, and 20 RCTs were finally included in the meta-analysis. The selection process is summarized in [Figure 1](#pone-0074872-g001){ref-type="fig"}. In total, 6,433 patients were investigated in these trials and they had a variety of cancers: NSCLC (twelve trials) [@pone.0074872-Crino1], [@pone.0074872-Sandler1], [@pone.0074872-Georgoulias1], [@pone.0074872-Cardenal1], [@pone.0074872-Sculier1], [@pone.0074872-Comella1], [@pone.0074872-Thomas1], [@pone.0074872-Ohe1], [@pone.0074872-Gronberg1], [@pone.0074872-Treat1], [@pone.0074872-Gridelli3], [@pone.0074872-Spigel1], breast cancer (three trials) [@pone.0074872-Zielinski1], [@pone.0074872-Feher1], [@pone.0074872-Brufsky1], pancreatic cancer (three trials) [@pone.0074872-Oettle1], [@pone.0074872-Ueno1], [@pone.0074872-ElKhoueiry1], bladder cancer (one trial) [@pone.0074872-vonderMaase1], Carcinoma of unknown (one trial) [@pone.0074872-Hainsworth1]. All included trials involved randomized treatment allocation. None were placebo controlled or double blind, and the median Jadad score was 2 (range = 2--3). Sample size were in the range of 50 to 1135 patients, with seven trials including \>400 patients each. According to the inclusion criteria of each trial, patients were required to have an adequate renal, hepatic and hematologic function. The median age of study participants was in the range of 53--77 years (some studies only reported the mean age). [Table 1](#pone-0074872-t001){ref-type="table"} reports the study and patient characteristics for the included trials.

![Selection process for randomized controlled trials included in the meta-analysis.](pone.0074872.g001){#pone-0074872-g001}
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###### Characteristics of 20 included trials in the meta-analysis (n = 6433).

![](pone.0074872.t001){#pone-0074872-t001-1}

  Studies                            Phase        Underlying malignancies        Enrolled patients (n)           Treatment arms            Patients for analysis   Median age (years)   Median treatment duration (months/cycles)   Median PFS/TTP (months)   Median OS (months)   Jadad score      Reported bleeding events
  --------------------------------- ------- ----------------------------------- ----------------------- --------------------------------- ----------------------- -------------------- ------------------------------------------- ------------------------- -------------------- ------------- --------------------------------
  **Cardenal F. et al 1999**          III                  NSCLC                          135             GEM 1250 mg/m^2^+CDDP q.3.w.              69                     59                              4.1                                6.9                    8.7                2                  Hemorrhage
                                                                                                                VP-16+CDDP q.3.w.                   66                     58                              3.1                                4.3                    7.2                        
  **Crino L. et al 1999**             III                  NSCLC                          370             GEM 1000 mg/m^2^+CDDP q.4.w.              152                    62                           4 cycles                              5.0                    8.6                2                  Hemorrhage
                                                                                                                   MIC q.4.w.                       148                    60                           4 cycles                              4.8                    9.6                        
  **Sandler A.B. et al 2000**         III                  NSCLC                          522             GEM 1000 mg/m^2^+CDDP q.4.w.              260                    62                           4 cycles                              5.6                    9.1                2                  Hemorrhage
                                                                                                                   CDDP q.4.w.                      262                    63                           2 cycles                              3.7                    7.6                        
  **Von der Maase H. et al 2000**     III             Bladder cancer                      405             GEM 1000 mg/m^2^+CDDP q.4.w.              203                    63                              NR                                 5.8                    13.8               2                  Hemorrhage
                                                                                                                   MVAC q.4.w.                      202                    63                              NR                                 4.6                    14.8                       
  **Sculier J.P. 2002**               III                  NSCLC                          284            GEM1000 mg/m^2^+CDDP+CBP q.4.w.            92                     NR                            86 days                              NR                   34 weeks             2                   Bleeding
                                                                                                           GEM 1000 mg/m^2^+IFO q.4.w.              94                     NR                            84 days                              NR                   30 weeks                     
                                                                                                               CDDP+CBP+IFO q.4.w.                  94                     NR                            84 days                              NR                   24 weeks                     
  **Comella P et al. 2004**           II                   NSCLC                          264                GEM 1200 mg/m^2^ q.4.w.                68                     75                              NR                                 3.3                    5.1                3                   Bleeding
                                                                                                                   PTX q.4.w.                       63                     72                              NR                                 3.7                    6.4                        
                                                                                                           GEM 1000 mg/m^2^+PTX q.3.w.              68                     72                              NR                                 4.1                    9.2                        
                                                                                                                 GEM+NVB q.3.w.                     65                     73                              NR                                 4.5                    9.7                        
  **Feher O. et al 2005**             III                   MBC                           410                GEM 1200 mg/m^2^ q.4.w.                198                    69                          3.5 cycles                             3.4                    11.8               2                  Hemorrhage
                                                                                                                   EPI q.4.w.                       199                    68                          4.6 cycles                             6.1                    19.1                       
  **Georgoulias V. et al 2005**       III                  NSCLC                          413              GEM 1000 mg/m^2^+DOC q.3.w.              197                    63                           4 cycles                               4                     9.0                2                 GI bleeding
                                                                                                                 NVB+CDDP q.3.w.                    192                    64                           4 cycles                               5                     9.7                        
  **Zielinski C. et al 2005**         III                   MBC                           259            GEM 1000 mg/m^2^+EPI+PTX q.3.w.            130                    53                           7 cycles                              9.1                    29.5               2                   Bleeding
                                                                                                                FU+EPI+CTX q.3.w.                   122                    54                           8 cycles                              9.0                    24.9                       
  **Thomas P. et al 2006**            II                   NSCLC                          100              GEM 1250 mg/m^2^+CBP q.3.w.              51                     60                           4 cycles                           140 days                334 days             2                   Bleeding
                                                                                                                 NVB+CDDP q.3.w.                    49                     56                           3 cycles                           148 days                304 days                     
  **Oettle H. et al 2007**            III            Pancreatic cancer                    368                GEM 1000 mg/m^2^ q.4.w.                186                    62                           6 cycles                             13.4                    22.1               3                   Bleeding
                                                                                                                   Observation                      182                    61                              --                                 6.9                    20.2                       
  **Ohe Y. et al 2007**               III                  NSCLC                          602              GEM 1000 mg/m^2^+DDP q.3.w.              151                    61                              NR                                 3.2                    14.0               2             Cerebral hemorrhage
                                                                                                                 PTX+CBP q.3.w.                     148                    63                              NR                                 3.2                    12.3                       
                                                                                                               CPT-11+CDDP q.4.w.                   147                    62                              NR                                 3.3                    13.9                       
                                                                                                                 NVB+DDP q.3.w.                     146                    61                              NR                                 3.0                    11.4                       
  **Gronberg B.H. et al 2009**        III                  NSCLC                          436              GEM 1000 mg/m^2^+CBP q.3.w.              217                    66                          3.1 cycles                             NR                     7.0                2                   Bleeding
                                                                                                                 PEM+CBP q.3.w.                     219                    64                          3.3 cycles                             NR                     7.3                        
  **Ueno H. et al. 2009**             III            Pancreatic cancer                    119            Gemcitabine 1000 mg/m^2^ q.4.w.            57                     65                           3 cycles                             11.4                    22.3               2                 GI bleeding
                                                                                                                   Observation                      60                     64                              --                                 5.0                    18.4                       
  **Hainsworth J.D. et al. 2010**     III    Carcinoma of unknown primary site            198            GEM 1000 mg/m^2^+CPT-11 q.3.w.             105                    59                           4 cycles                              5.3                    8.5                3                   Bleeding
                                                                                                              PTX+CBP+ VP-16 q.3.w.                 93                     61                           3 cycles                              3.3                    7.4                        
  **Treat J.A. et al 2010**           III                  NSCLC                         1135              GEM 1000 mg/m^2^+CBP q.3.w.              356                   64.1                          4 cycles                              4.3                    7.9                2                  Hemorrhage
                                                                                                           GEM 1000 mg/m^2^+PTX q.3.w.              355                   64.3                          4 cycles                              4.5                    8.5                        
                                                                                                                 PTX+CBP q.3.w.                     366                   64.1                          4 cycles                              4.7                    8.7                        
  **Brufsky A. et al 2011**           II                    MBC                           191            GEM 1500 mg/m^2^+PTX+BEV q.4.w.            93                    55.2                          6 cycles                             11.3                    24.3               3            Epistaxis, hemorrhage
                                                                                                                 PTX+BEV q.4.w.                     94                    57.5                          6 cycles                              8.8                    25.0                       
  **Gridlli C. et al 2011**           II                   NSCLC                          60               GEM 1200 mg/m^2^+SOR q.3.w.              31                     74                              NR                              8.1 weeks                 6.6                2        Pulmonary hemorrhage, bleeding
                                                                                                                 SOR+ erlotinib                     29                     76                              NR                              12.7weeks                 12.6                       
  **EI-Khoueiry A.B. et al 2012**     II             Pancreatic cancer                    52               GEM 1000 mg/m^2^+SOR q.3.w.              37                     65                           2 cycles                              2.9                    6.5                2                 GI bleeding
                                                                                                                       SOR                          15                     66                           2 cycles                              2.3                    4.3                        
  **Spigel D.R. et al 2012**          II                   NSCLC                          110            GEM 1500 mg/m^2^+PEM+BEV q.4.w.            55                     76                          2.5 cycles                             4.7                    7.5                2             Pulmonary hemorrhage
                                                                                                               PEM+CBP+BEV q.3.w.                   55                     77                           6 cycles                             10.2                    14.8                       

Abbreviation: GEM, gemcitabine; CDDP, cisplatin; VP-16, etoposide; DOC, docetaxel; MIC, Mitomycin+IFO+cisplatin; MVAC, methotrexate+vinblastine+doxorubicin+cisplatin; CBP, carboplatin; IFO, ifosfamide; EPI, epirubicin; NVB, vinorelbine; PTX, paclitaxel; FU, fluorouracil; CTX, cyclophosphamide; PEM, pemetrexed; CPT-11, irinotecan; BEV, bevacizumab; SOR, sorafenib; GI, gastrointestinal tract; NSCLC, non-small-cell lung cancer; MBC; metastatic breast cancer; PFS, progression-free survival; TTP, time-to progression; OS, overall survival; NR, not reported;

Publication Bias {#s3b}
----------------

No evidence of publication bias was detected for the RR of high-grade hemorrhagic events in this study by either Begg or Egger's test (Begg's test *p* = 0.81; Egger's test *p* = 0.21).

Incidence of High-grade Hemorrhage {#s3c}
----------------------------------

A total of 6433 patients were included in the analysis. In the gemcitabine group, 53 patients experienced high-grade hemorrhage compared with 18 patients in the non-gemcitabine group. The highest incidence (23.5%; 95% CI, 13.9%--37.0%) as observed in a phase II NSCLC trial [@pone.0074872-Thomas1], and the lowest incidence was observed in five trials in which no hemorrhagic events occurred [@pone.0074872-Georgoulias1], [@pone.0074872-Sculier1], [@pone.0074872-Comella1], [@pone.0074872-Ohe1], [@pone.0074872-Brufsky1]. Using a random-effects model (heterogeneity test: Q = 81.314; *P*\<0.001; *I* ^2^ = 77%), the summary incidence of high-grade hemorrhagic events in patients receiving gemcitabine-based therapy was 1.7% (95% CI, 0.9%--3.1%, [Figure 2](#pone-0074872-g002){ref-type="fig"}).

![Incidence of high-grade hemorrhagic events associated with gemcitabine.](pone.0074872.g002){#pone-0074872-g002}

Relative Risk of High-grade Hemorrhage {#s3d}
--------------------------------------

To investigate the specific contribution of gemcitabine to the development of hemorrhagic events and exclude the influence of confounding factors such as underlying malignancy, and other therapeutic interventions, we therefore determined the relative risk (RR) of gemcitabine associated hemorrhagic events. The combined results demonstrated that the use of gemcitabine was associated with a significantly increased risk of developing high-grade hemorrhage with a RR of 2.727 (95%CI: 1.581--4.702, p\<0.001, [Figure 3](#pone-0074872-g003){ref-type="fig"}). We also did sensitivity analysis to examine the stability and reliability of pooled RRs by sequential omission of individual studies. The results indicated that the significance estimate of pooled RRs was not significantly influenced by omitting any single study ([Figure 4](#pone-0074872-g004){ref-type="fig"}).

![Relative risk of high-grade hemorrhagic events associated with gemcitabine-based vs non-gemcitabine-based therapy.](pone.0074872.g003){#pone-0074872-g003}

![Meta-analysis of high-grade hemorrhagic events associated with gemcitabine-based vs non-gemcitabine-based therapy: "leave-one-out" sensitivity analysis.](pone.0074872.g004){#pone-0074872-g004}

Influence of Underlying Tumor Type on RR of High-grade Hemorrhage {#s3e}
-----------------------------------------------------------------

To better determine possible relationships between gemcitabine and high-grade hemorrhage, we performed several prespecified subgroup analyses, stratifying patients by malignancy, phase of trial and year of publication ([Table 2](#pone-0074872-t002){ref-type="table"}). The incidence of severe hemorrhage was highest among patients with NSCLC (2.0%, 95%CI: 0.8--4.6%), followed by pancreatic cancer (1.4%, 95%CI: 0.4--4.1%) and MBC (1.0%, 95%CI: 0.3--2.7%). The effect sizes varied, and the highest RR of hemorrhage was observed in non-small-cell lung cancer patients (RR: 3.234; 95%CI, 1.678--6.233; *p*\<0.001), but the differences among tumor types were not statistically significant.

10.1371/journal.pone.0074872.t002

###### Relative risk of high-grade hemorrhage based on prespecified subgroups.

![](pone.0074872.t002){#pone-0074872-t002-2}

  Group                                                              No. of trials   Gemcitabine arm   Non-gemcitabine arm   I^2^,%   Relative risk (95%CI)   *P* for relative risk   *P* for group difference                                         
  ----------------------------------------------------------------- --------------- ----------------- --------------------- -------- ----------------------- ----------------------- -------------------------- ----- ---------------------- --------- -------
  **Overall**                                                             20               53                 3227            1.7              18                     3014                      1.2              0%    2.272 (1.581--4.702)   \<0.001    NA
  **Tumor type**                                                                                                                                                                                                                                       
  NSCLC                                                                   12               12                 2218            2.0              12                     2047                      1.0              20%   3.234 (1.678--6.233)   \<0.001   0.444
  Pancreas                                                                 3                3                  280            1.4               0                      257                      0.0              0%    2.259 (0.362--14.12)    0.383   
  MBC                                                                      3                3                  421            1.0               1                      415                      0.6              0%    2.955 (0.299--29.24)    0.354   
  Others                                                                   2                5                  308            1.7               5                      295                      1.8              0%    0.972 (0.285--3.321)    0.964   
  **Phase of trials**                                                                                                                                                                                                                                  
  Phase II                                                                 6               15                  403            2.6               2                      370                      1.4              43%   7.053 (1.591--31.27)    0.01     0.524
  Phase III                                                               14               38                 2824            1.6              16                     2644                      0.9              0%    2.211 (1.211--4.038)    0.01    
  **Publication year**                                                                                                                                                                                                                                 
  1999--2005                                                               9               17                 1531            1.6               9                     1413                      1.0              0%    1.808 (0.806--4.057)    0.151    0.278
  2006--2012                                                              11               36                 1696            2.1               9                     1601                      1.2              0%    3.750 (1.735--8.108)   \<0.001  
  **Gemcitabine-based regimens** [1](#nt103){ref-type="table-fn"}                                                                                                                                                                                      
  Single agent                                                             4                3                  509            0.8               0                      504                       0               0%     7.48 (0.78--71.92)     0.081    0.876
  Doublet combination                                                     14               47                 2413            2.0              17                     2237                      1.3              8%     2.41 (1.45--3.99)     \<0.001  
  Triplet combination                                                      4                3                  370            1.2               2                      365                      0.9              0%     1.47 (0.25--8.47)      0.67    

Abbreviation: NSCLC, non-small-cell lung cancer; MBC, metastatic breast cancer;

gemcitabine is used as single agent and combination therapy in two clinical trials, thus there is a total of 22 comparisons.

Influence of Phase of Trials on RR of High-grade Hemorrhage {#s3f}
-----------------------------------------------------------

Given the potentially differing risks of hemorrhage between phase II and III trials, an exploratory analysis stratifying patients by phase of trial was performed ([Table 2](#pone-0074872-t002){ref-type="table"}). Interestingly, the effect size was greater in the phase II trials (RR 7.053, 95%CI: 1.591--31.27) versus phase III trials (RR 2.211, 95%CI: 1.211--4.038). However, there was no significant difference between these subgroups.

Influence of Publication Year on RR of High-grade Hemorrhage {#s3g}
------------------------------------------------------------

We hypothesized that the incidence of severe hemorrhage reported in cancer clinical trials may have increased over the past decade. Therefore, we explored the impact of publication year on incidence and RR of severe hemorrhage with gemcitabine-based therapy. Notably, the incidence of hemorrhage in the 9 trials published from 1999 to 2005 was 2.1% (95%CI: 0.8--5.4%), compared with an incidence of 1.6% (95%CI: 0.9--2.6%) in the 11 trials published from 2006 to 2012. In the 11 trials published from 2005 to 2012, gemcitabine-based therapy was associated with an RR of hemorrhage of 3.75 (95%CI, 1.735--8.108). In trials published from 1999 to 2005, gemcitabine-based therapy was associated with an RR of hemorrhage of 1.808 (95%CI, 0.806--4.057). This difference did not reach statistical significance.

Influence of Treatment Regimes on RR of High-grade Hemorrhage {#s3h}
-------------------------------------------------------------

Concomitant agents with gemcitabine, including bevacizumab and sorafenib, might increase the risk of gemcitabine-related hemorrhage events. We therefore performed sub-group analysis according to gemcitabine-based regimens. An increased risk of hemorrhage events was observed in gemcitabine used as single agent (RR 7.48, 95%∶0.78--71.92), doublet combination (RR 2.41, 95%CI: 1.45--3.99) and triplet combination (RR 1.47, 95%CI: 0.25--8.47) when compared to controls, though the risk did not significantly increase in gemcitabine therapy used as single agent (p = 0.081) and triplet combination (p = 0.67) ([Table 2](#pone-0074872-t002){ref-type="table"}). One possible explanation for this finding was that there were a limited number of trials to investigate the risk of hemorrhage events in gemcitabine used as single agent and triplet combination, thus the power to investigate the risk was small. Interestingly, the effect size was greater in gemcitabine used as single agent versus gemcitabine combination, which suggested that concomitant agents with gemcitabine had limited effects on the risk of gemcitabine-related hemorrhage events.

Discussion {#s4}
==========

To our best knowledge, this is the first meta-analysis to investigate the risk of high-grade hemorrhage associated with gemcitabine. Our analysis of data from randomized controlled trials shows a nearly three-times increased risk of high-grade hemorrhage in cancer patients treated with gemcitabine-based therapy. Additionally, the overall incidence of gemcitabine associated high-grade hemorrhagic events is 1.7% (95% CI, 0.9%--3.1%). Based on these results, we could conclude that while the incidence of high-grade hemorrhage in patients treated with gemcitabine is low, the use of gemcitabine is associated with significantly increased risk of high-grade hemorrhage when compared with non-gemcitabine-based therapy. These results would provide important information for clinicians who use gemcitabine to treat patients with solid cancer.

Many factors such as age, race, sex, mobility, underlying cancer, and concurrent use of anticoagulants or chemotherapy are known to contribute to the development of hemorrhage in cancer patients [@pone.0074872-Gorter1]. Thus, we also explore the risk factors for gemcitabine associated hemorrhagic events. Our exploratory subgroup analyses reveal some interesting hypothesis-generating findings. The effect sizes vary with regard to the RR of hemorrhage in specific tumor types, and the highest RR of serious hemorrhage is observed in non-small-cell lung cancer patients (RR: 3.234; 95%CI, 1.678--6.233; *p*\<0.001). However, the interpretation of these findings is hampered by the low number of patients and events in certain subgroups. As a result, more high-quality trials are still needed to investigate the risk of gemcitabine associated hemorrhage in these tumors. We hypothesize that the incidence of serious hemorrhage reported in clinical trials over the last decade may have increased because of an increased awareness that serious hemorrhage may be treatment rather than disease related. Indeed, the incidence of serious hemorrhage is higher in trials published between 2006 and 2012 compared with trials published between 1999 and 2005. Then, we also investigate the differing risks of hemorrhage between phase II and III trials. Interestingly, the effect size is greater in the phase II trials versus phase III trials. However, there is no significant difference between these subgroups. Finally, we perform sub-group analysis to detect the influence of concomitant agents on risk of hemorrhage, and find that there is an increased risk of hemorrhage events in gemcitabine used as single agent, doublet combination and triplet combination when compared to controls, though the risk did not significantly increase in gemcitabine therapy used as single agent and triplet combination.

The pathogenesis of gemcitabine-induced hemorrhage remains unclear, gemcitabine-induced thrombocytopenia may be directly related to its increased risk of hemorrhage, but the risk of hemorrhage depends not only the platelet count, but also on the underlying disease, platelet function and complications such as fever and infection or the presence of coagulation defects [@pone.0074872-Avvisati1]. It is unknown whether gemcitabine affects the coagulation cascade or endothelial cell. As a result, studies focusing on this issue are still needed.

Our meta-analysis had several limitations. First, this meta-analysis was not based on individual patient data, and meta-analyses based on published data tended to overestimate treatment effects compared with individual patient data analyses. In addition, it precluded a more comprehensive analysis such as adjusting for baseline factors and other differences that existed between the trials from which the data were pooled. Therefore, the results must be interpreted cautiously, as an individual patient data-based meta-analysis would give more reliable estimation than one based on published data. Secondly, trials reported zero high-grade hemorrhage in one or both arms were also included for analysis. In this setting, using fixed effects models and continuity corrections would bias the results towards null. But we felt that including trials reporting zero high-grade hemorrhage would provide the most conservative estimate. Thirdly, different treatment strategy, duration, and regimens contributed to increase the clinical heterogeneity of the meta-analysis, which made the interpretation of the meta-analysis more problematic, although we performed sub-group analysis and sensitive analysis. Additionally, targeted drugs including bevacizumab [@pone.0074872-Hapani1], [@pone.0074872-Hang1] and sorafenib [@pone.0074872-Je1], could increased the risk of hemorrhage, which is another potential bias for evaluating the risk of hemorrhage by gemcitabine.

In conclusion, although the incidence of high-grade hemorrhage in patients treated with gemcitabine is low, a significantly increased risk of high-grade hemorrhage is detected when compared with non-gemcitabine therapy. Clinicians should be cautious when using gemcitabine-based therapy for treating cancer patients, especially those at high risk.
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